Waters Corporation (0LTI.L)
USD 325.39
(-5.2%)
USD 325.39
(-5.2%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.3 Billion USD | 46.39% |
| 2022 | 1.57 Billion USD | 4.03% |
| 2021 | 1.51 Billion USD | 11.6% |
| 2020 | 1.35 Billion USD | -17.67% |
| 2019 | 1.64 Billion USD | 43.5% |
| 2018 | 1.14 Billion USD | -39.49% |
| 2017 | 1.89 Billion USD | 11.49% |
| 2016 | 1.7 Billion USD | 13.99% |
| 2015 | 1.49 Billion USD | 20.41% |
| 2014 | 1.24 Billion USD | 4.2% |
| 2013 | 1.19 Billion USD | 13.88% |
| 2012 | 1.04 Billion USD | 49.29% |
| 2011 | 700 Million USD | 0.0% |
| 2010 | 700 Million USD | 40.0% |
| 2009 | 500 Million USD | 0.0% |
| 2008 | 500 Million USD | 0.0% |
| 2007 | 500 Million USD | 0.0% |
| 2006 | 500 Million USD | 0.0% |
| 2005 | 500 Million USD | 100.0% |
| 2004 | 250 Million USD | 100.0% |
| 2003 | 125 Million USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | -100.0% |
| 1999 | 81.1 Million USD | -62.85% |
| 1998 | 218.3 Million USD | -28.5% |
| 1997 | 305.3 Million USD | 45.04% |
| 1996 | 210.5 Million USD | 32.81% |
| 1995 | 158.5 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 1.82 Billion USD | -8.96% |
| 2024 Q2 | 2 Billion USD | 0.01% |
| 2024 Q1 | 2 Billion USD | -13.0% |
| 2023 Q4 | 2.3 Billion USD | -6.1% |
| 2023 Q2 | 2.58 Billion USD | 80.42% |
| 2023 FY | 2.3 Billion USD | 46.39% |
| 2023 Q1 | 1.43 Billion USD | -9.19% |
| 2023 Q3 | 2.45 Billion USD | -4.84% |
| 2022 Q1 | 1.44 Billion USD | -4.61% |
| 2022 FY | 1.57 Billion USD | 4.03% |
| 2022 Q4 | 1.57 Billion USD | 1.96% |
| 2022 Q3 | 1.54 Billion USD | 4.06% |
| 2022 Q2 | 1.48 Billion USD | 2.79% |
| 2021 FY | 1.51 Billion USD | 11.6% |
| 2021 Q1 | 1.7 Billion USD | 25.55% |
| 2021 Q4 | 1.51 Billion USD | -6.18% |
| 2021 Q2 | 1.6 Billion USD | -5.86% |
| 2021 Q3 | 1.61 Billion USD | 0.64% |
| 2020 Q3 | 1.57 Billion USD | -7.36% |
| 2020 Q4 | 1.35 Billion USD | -13.67% |
| 2020 FY | 1.35 Billion USD | -17.67% |
| 2020 Q1 | 1.9 Billion USD | 15.9% |
| 2020 Q2 | 1.69 Billion USD | -11.18% |
| 2019 FY | 1.64 Billion USD | 43.5% |
| 2019 Q4 | 1.64 Billion USD | 25.11% |
| 2019 Q1 | 1.11 Billion USD | -2.8% |
| 2019 Q3 | 1.31 Billion USD | 18.1% |
| 2019 Q2 | 1.11 Billion USD | -0.09% |
| 2018 Q3 | 1.14 Billion USD | 0.01% |
| 2018 Q1 | 1.24 Billion USD | -34.25% |
| 2018 Q4 | 1.14 Billion USD | 0.01% |
| 2018 FY | 1.14 Billion USD | -39.49% |
| 2018 Q2 | 1.14 Billion USD | -7.99% |
| 2017 Q1 | 1.64 Billion USD | -3.52% |
| 2017 Q4 | 1.89 Billion USD | 9.53% |
| 2017 Q3 | 1.73 Billion USD | 2.68% |
| 2017 Q2 | 1.68 Billion USD | 2.75% |
| 2017 FY | 1.89 Billion USD | 11.49% |
| 2016 Q2 | 1.63 Billion USD | 2.41% |
| 2016 FY | 1.7 Billion USD | 13.99% |
| 2016 Q4 | 1.7 Billion USD | 2.72% |
| 2016 Q3 | 1.65 Billion USD | 1.54% |
| 2016 Q1 | 1.59 Billion USD | 6.72% |
| 2015 Q3 | 1.45 Billion USD | 5.05% |
| 2015 Q4 | 1.49 Billion USD | 2.61% |
| 2015 Q1 | 1.31 Billion USD | 5.65% |
| 2015 Q2 | 1.38 Billion USD | 5.73% |
| 2015 FY | 1.49 Billion USD | 20.41% |
| 2014 Q4 | 1.24 Billion USD | 2.9% |
| 2014 Q1 | 1.1 Billion USD | -7.56% |
| 2014 Q2 | 1.16 Billion USD | 5.45% |
| 2014 Q3 | 1.2 Billion USD | 3.88% |
| 2014 FY | 1.24 Billion USD | 4.2% |
| 2013 Q2 | 1.13 Billion USD | 3.18% |
| 2013 FY | 1.19 Billion USD | 13.88% |
| 2013 Q4 | 1.19 Billion USD | 2.59% |
| 2013 Q3 | 1.16 Billion USD | 2.2% |
| 2013 Q1 | 1.1 Billion USD | 5.26% |
| 2012 Q1 | 700 Million USD | 0.0% |
| 2012 Q2 | 700 Million USD | 0.0% |
| 2012 Q3 | 700 Million USD | 0.0% |
| 2012 Q4 | 1.04 Billion USD | 49.29% |
| 2012 FY | 1.04 Billion USD | 49.29% |
| 2011 Q2 | 400 Million USD | 0.0% |
| 2011 FY | 700 Million USD | 0.0% |
| 2011 Q1 | 400 Million USD | -42.86% |
| 2011 Q3 | 700 Million USD | 75.0% |
| 2011 Q4 | 700 Million USD | 0.0% |
| 2010 Q1 | 700 Million USD | 40.0% |
| 2010 FY | 700 Million USD | 40.0% |
| 2010 Q4 | 700 Million USD | 0.0% |
| 2010 Q3 | 700 Million USD | 0.0% |
| 2010 Q2 | 700 Million USD | 0.0% |
| 2009 Q2 | 500 Million USD | 0.0% |
| 2009 FY | 500 Million USD | 0.0% |
| 2009 Q4 | 500 Million USD | 0.0% |
| 2009 Q3 | 500 Million USD | 0.0% |
| 2009 Q1 | 500 Million USD | 0.0% |
| 2008 Q2 | 650 Million USD | 0.0% |
| 2008 FY | 500 Million USD | 0.0% |
| 2008 Q4 | 500 Million USD | -23.08% |
| 2008 Q1 | 650 Million USD | 30.0% |
| 2008 Q3 | 650 Million USD | 0.0% |
| 2007 Q2 | 500 Million USD | 0.0% |
| 2007 Q4 | 500 Million USD | 0.0% |
| 2007 Q3 | 500 Million USD | 0.0% |
| 2007 Q1 | 500 Million USD | 0.0% |
| 2007 FY | 500 Million USD | 0.0% |
| 2006 Q1 | 500 Million USD | 0.0% |
| 2006 Q3 | 500 Million USD | 0.0% |
| 2006 Q4 | 500 Million USD | 0.0% |
| 2006 FY | 500 Million USD | 0.0% |
| 2006 Q2 | 500 Million USD | 0.0% |
| 2005 Q2 | 250 Million USD | 0.0% |
| 2005 Q4 | 500 Million USD | 100.0% |
| 2005 FY | 500 Million USD | 100.0% |
| 2005 Q1 | 250 Million USD | 0.0% |
| 2005 Q3 | 250 Million USD | 0.0% |
| 2004 Q2 | 115 Million USD | -4.17% |
| 2004 Q3 | 110 Million USD | -4.35% |
| 2004 Q1 | 120 Million USD | -4.0% |
| 2004 FY | 250 Million USD | 100.0% |
| 2004 Q4 | 250 Million USD | 127.27% |
| 2003 Q3 | 23.33 Million USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 FY | 125 Million USD | 0.0% |
| 2003 Q4 | 125 Million USD | 435.74% |
| 2003 Q2 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2000 FY | - USD | -100.0% |
| 2000 Q1 | 42.3 Million USD | -47.84% |
| 2000 Q2 | 2.91 Million USD | -93.11% |
| 2000 Q3 | 13.51 Million USD | 363.46% |
| 2000 Q4 | - USD | -100.0% |
| 1999 Q4 | 81.1 Million USD | -28.23% |
| 1999 FY | 81.1 Million USD | -62.85% |
| 1999 Q1 | 180.6 Million USD | -17.27% |
| 1999 Q2 | 144.4 Million USD | -20.04% |
| 1999 Q3 | 113 Million USD | -21.75% |
| 1998 Q1 | 293 Million USD | -4.03% |
| 1998 FY | 218.3 Million USD | -28.5% |
| 1998 Q2 | 279.4 Million USD | -4.64% |
| 1998 Q3 | 252.2 Million USD | -9.74% |
| 1998 Q4 | 218.3 Million USD | -13.44% |
| 1997 Q2 | 179.6 Million USD | -7.9% |
| 1997 Q3 | 339.2 Million USD | 88.86% |
| 1997 Q4 | 305.3 Million USD | -9.99% |
| 1997 FY | 305.3 Million USD | 45.04% |
| 1997 Q1 | 195 Million USD | -7.36% |
| 1996 FY | 210.5 Million USD | 32.81% |
| 1996 Q1 | 143.1 Million USD | -9.72% |
| 1996 Q2 | 236.3 Million USD | 65.13% |
| 1996 Q4 | 210.5 Million USD | -6.98% |
| 1996 Q3 | 226.3 Million USD | -4.23% |
| 1995 Q1 | 267.4 Million USD | 0.0% |
| 1995 Q4 | 158.5 Million USD | -38.18% |
| 1995 Q2 | 264.9 Million USD | -0.93% |
| 1995 FY | 158.5 Million USD | 0.0% |
| 1995 Q3 | 256.4 Million USD | -3.21% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -1672.585% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -3945.611% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -494.422% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -4945.659% |
| bluebird bio, Inc. | 224.41 Million USD | -927.325% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -6117.84% |
| Imunon, Inc. | 1.13 Million USD | -202263.483% |
| Editas Medicine, Inc. | 24.37 Million USD | -9359.679% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 82.204% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | -16.702% |
| Myriad Genetics, Inc. | 130.9 Million USD | -1661.278% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -792.572% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -6845.153% |
| Verastem, Inc. | 40.08 Million USD | -5651.417% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 71.339% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 92.636% |
| Biogen Inc. | 7.18 Billion USD | 67.926% |
| Nektar Therapeutics | 112.62 Million USD | -1947.07% |
| Perrigo Company plc | 3.63 Billion USD | 36.536% |
| Dynavax Technologies Corporation | 252.41 Million USD | -813.371% |
| Illumina, Inc. | 1.48 Billion USD | -54.836% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -71087.888% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -230451.3% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -1226.891% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -9694.439% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | -288.726% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -6779.048% |
| Evolus, Inc. | 120.35 Million USD | -1815.53% |
| Adicet Bio, Inc. | 17.7 Million USD | -12923.29% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -74900.423% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 14.702% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -359.681% |
| FibroGen, Inc. | 89.69 Million USD | -2470.335% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 15.703% |
| OPKO Health, Inc. | 222.03 Million USD | -938.36% |
| Homology Medicines, Inc. | 43.17 Million USD | -5239.802% |
| Geron Corporation | 35.05 Million USD | -6477.596% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 1.601% |
| Exelixis, Inc. | 189.94 Million USD | -1113.786% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -246215.491% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -2283.033% |
| Zoetis Inc. | 6.56 Billion USD | 64.876% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -1194.723% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -52274.216% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | -218.133% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -6643.238% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | -64.635% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | -103.575% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | -53.778% |
| Blueprint Medicines Corporation | 610.96 Million USD | -277.358% |
| Insmed Incorporated | 1.19 Billion USD | -93.196% |
| TG Therapeutics, Inc. | 100.11 Million USD | -2202.796% |
| Incyte Corporation | 29.16 Million USD | -7805.881% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -416.352% |